Dr Mark McClure

Qualifications

MBBS, University of Wales, College of Medicine, Cardiff, 2008

MRCP 2012

MRCP Specialty Certificate Examination in Nephrology / ESENeph, 2022

GMC Full Registration No. 7015020

PhD in Medicine, University of Cambridge, 2022

CCT in Renal and General Internal Medicine, East of England Deanery, 2023

Professional bodies (Positions held in last 3 years)

GMC Full Registration No. 7015020

MDU Registration No. 460928D

Publications

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol. McClure, M.E, Gopaluni, S, Wason, J. et al. Trials. 2023.

Age and time-dependent increase in incident anti-glomerular basement membrane (anti-GBM) disease: a nation-wide cohort study. Karl Emil Nelveg-Kristensen, Bo Madsen, Mark McClure, et al. CKJ. 2023

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction Models. Mark E McClure, Yajing Zhu, Rona M Smith, et al. Rheumatology. 2021

Treatment of Relapses in ANCA-Associated Vasculitis. McClure M, Jones RB. Clinical Journal of American Society of Nephrology. 2019.

Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. McClure ME, Wason J, Gopaluni S, et al. Journal of Clinical Rheumatology. 2019

B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. McClure M, Gopaluni S, Jayne D, Jones R. Nature Reviews Rheumatology. 2018

Long-term graft outcomes and patient survival are lower post-transplant in patients with a primary renal diagnosis of glomerulonephritis. Rishi Pruthi, Mark McClure, Anna Casula, et al. Kidney International 2016

Treatments and areas of interest

• Chronic kidney disease (CKD)
• Hypertension (high blood pressure)
• Diabetic kidney disease
• Proteinuria (protein in the urine)
• Acute kidney injury
• Glomerulonephritis
• Kidney stones
• Also providing specialist inpatient nephrology opinion at Kingsbridge Hospital on request